leridistim
Recombinant proteinexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1999 (NCT00004215)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-3Supplementation
IL3 supplementation
- Granulocyte colony-stimulating factorSupplementation
CSF3 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108421 ↗
Also known as
- 14-125 interleukin-3(14-alanine, 50-aspartic acid), granulocyte colony stimulating factor(17-serine) fusion protein
- leridistim
- leridistim
- leridistim
- myelopoietin sc-70935
- sc-70935
- sc-70935
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00004215 | Phase 2 | Aug 1, 1999 | Cornell University, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1999 |
2 organizations
Page 1 / 1